ReviewThe Journal of steroid biochemistry and molecular biology2009
Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action.
Review in The Journal of steroid biochemistry and molecular biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 180 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
180 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Integrative analyses of genes related to femoral head osteonecrosis: an umbrella review of systematic reviews and meta-analyses of observational studies.Journal of orthopaedic surgery and research · 2022Pooled it
- Association of ABCB1 C3435T polymorphism with the susceptibility to osteonecrosis of the femoral head: A meta-analysis.Medicine · 2017Pooled it
- Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study.Canadian journal of surgery. Journal canadien de chirurgie · 2015Trial
- Osteonecrosis in children after allogeneic hematopoietic cell transplantation: study of prevalence, risk factors and longitudinal changes using MR imaging.Bone marrow transplantation · 2012Trial
- From Physicochemical Properties to Rehabilitation Outcomes: Understanding Corticosteroid Injection Adverse Effects.International journal of molecular sciences · 2026Review
- Evidence-Based Management and Functional Outcomes of Femoral Head Avascular Necrosis: A Systematic Review.Cureus · 2026Review
- Advances in the mechanism for steroid-induced osteonecrosis of the femoral head.Bone research · 2026Review
- Suppression of exosomal miR-199a-3p, a differentially expressed miRNA in steroid-induced osteonecrosis of the femoral head, promotes cell proliferation, osteogenesis, and angiogenesis while inhibiting dexamethasone-induced apoptosis.Frontiers in bioengineering and biotechnology · 2026Article
- Osteoimmune microenvironmental failure in osteonecrosis of the femoral head: a necrosis-inflammation-repair loop and immune-editing-inspired framework for hip preservation.Frontiers in immunology · 2026Review
- GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway.Communications biology · 2025Article
- A predictive nomogram for treatment response in osteonecrosis patients receiving denosumab with UKA: integrating bone turnover markers and functional parameters.Endocrine connections · 2025Article
- Glucocorticoids induce femoral head necrosis in rats through the HIF-1α/VEGF signaling pathway.Scientific reports · 2025Article
- Relieving oxidative stress microenvironment and promoting vascularized bone formation to treat femoral head necrosis using 3D-printed scaffold with ultralong-term multienzyme-like activity.Journal of orthopaedic translation · 2025Article
- Mpox Infection and Endocrine Health: Bridging the Knowledge Gap.Medicina (Kaunas, Lithuania) · 2025Review
- Exploring molecular disparities of H-type vasculature endothelial cells in osteonecrosis of the femoral head through single-cell analysis.BMC musculoskeletal disorders · 2025Article
- Avascular necrosis in pediatric rheumatic diseases: an Italian retrospective multicentre study.Italian journal of pediatrics · 2025Article
- Article
- Emerging perspectives on osteonecrosis of the femoral head: the role of circular RNAs and long non-coding RNAs - a systematic review.Frontiers in genetics · 2025Review
- Immunomodulatory Mechanisms of Rehmanniae Radix Praeparata-Achyranthes Root-Chinese Angelica Root Combination in Nontraumatic Osteonecrosis of the Femoral Head: A Comprehensive Network Pharmacology and Molecular Docking Study Focusing on Immunological Pathways.Mediators of inflammation · 2025Article
- Exosomes secreted from human-derived adipose stem cells prevent progression of osteonecrosis of the femoral head.Journal of orthopaedic surgery and research · 2024Article
120 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid (GC) usage is the most common non-traumatic cause of osteonecrosis of the femoral head (ON). Despite the strong association of GC with ON, the underlying mechanisms have been unclear. Investigators have proposed both direct and indirect effects of GC on cells. Indirect and direct mechanisms remain intimately related and often result in positive feedback loops to potentiate the disease processes. However, the direct effects, in particular apoptosis, have recently been shown to be increasingly important. Suppression of osteoblast and osteoclast precursor production, increased apoptosis of osteoblasts and osteocytes, prolongation of the lifespan of osteoclasts and apoptosis of endothelial cells (EC) are all direct effects of GC usage. Elevated blood pressure through several pathways may raise the risk of clot formation. High-dose GC also decreases tissue plasminogen activator activity (t-PA) and increases plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels increasing the procoagulant potential of GC. Inhibited angiogenesis, altered bone repair and nitric oxide metabolism can also result. Also, GC treatment modulates other vasoactive mediators such as endothelin-1, noradrenalin and bradykinin. Thus, GCs act as a regulator of local blood flow by modulating vascular responsiveness to vasoactive substances. Vasoconstriction induced in intraosseous femoral head arteries causes femoral head ischemia. GCs also cause ischemia through increased intraosseous pressure, which subsequently decreases the blood flow to the femoral head by apoptosis of ECs as well as elevating the level of adipogenesis and fat hypertrophy in the bone marrow. It is difficult to predict which patients receiving a specific dose of GC will develop ON, indicating individual differences in steroid sensitivity and the potential of additional mechanisms. The textbook model of ON is a multiple hit theory in which, with a greater number of risk factors, the risk of ON increases. While more effort is needed to better comprehend the role of GC in ON, newer data on GC action upon the endothelial cell and the regional endothelial bed dysfunction theory sheds new light on particular GC mechanisms. Better understanding of GC pathomechanisms can lead to better treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.